Table 3 Factors related to early neurologic deterioration after acute intracerebral hemorrhage

Number

32

94

Age (years)

60.2 ± 10.6

62.5 ± 10.1

0.270

Gender (male/female)

17/15

52/42

0.829

Body mass index (kg/m²)

24.8 ± 2.9

24.0 ± 3.5

0.253

Hypertension

20 (62.5%)

55 (58.5%)

0.691

Diabetes mellitus

12 (37.5%)

19 (20.2%)

0.050

Hyperlipidemia

10 (31.3%)

30 (31.9%)

0.944

Coronary heart disease

3 (9.4%)

7 (7.5%)

0.727

Cigarette smoking

11(34.4%)

36 (38.3%)

0.692

Alcohol drinking

11 (34.4%)

38 (40.4%)

0.544

Statin use

8 (25.0%)

25 (26.6%)

0.859

Anticoagulant use

2 (6.3%)

5 (5.3%)

0.843

Antiplatelet use

6 (18.8%)

12 (12.8%)

0.403

Antihypertensive use

17 (53.1%)

50 (53.2%)

0.995

Hypoglycemic use

10 (31.3%)

15 (16.0%)

0.061

Admission time (h)

10.4 (7.6–15.5)

9.0 (4.9–11.9)

0.127

Sampling time (h)

11.7 (9.0-17.4)

10.6 (6.5–13.7)

0.157

Systolic arterial pressure (mmHg)

137.4 ± 22.9

144.7 ± 22.8

0.119

Diastolic arterial pressure (mmHg)

83.5 ± 7.5

86.5 ± 10.4

0.080

Hemorrhage locations (lobar/deep)

7/25

26/68

0.520

Intraventricular hemorrhage

10 (31.3%)

21 (22.3%)

0.312

Subarachnoidal hemorrhage

4 (12.5%)

7 (7.5%)

0.469

NIHSS scores

12 (11–15)

9 (6–11)

< 0.001

Hematoma volume (ml)

22 (15–29)

11 (8–16)

< 0.001

Blood leucocyte count (×10⁹/l)

8.7 (6.2–11.0)

7.8 (6.3–9.6)

0.368

Blood glucose levels (mmol/l)

13.3 (10.1–18.5)

10.8 (9.1–12.4)

0.010

Serum sestrin2 levels (ng/ml)

14.0 (5.8–24.0)

4.6 (2.4–12.4)

< 0.001